TAU is a natural therapeutic target for MAPT-related FTD, and an attractive target for related tauopathies such as AD, as there is a strong correlation between the amount of NFTs and cognitive decline, and Mapt-KO mice are healthy. This evidence concerns the gene MAPT and tauopathy.